Brief: Lsl Pharma Group Reports Record Revenues And Second Quarter 2026 Results
25/08/2026 12:37
BRIEF-Lsl Pharma Group Reports Record Revenues And Second Quarter 2026 Results Aug 25 (Reuters) - LSL Pharma Group Inc LSL.V:
LSL PHARMA GROUP REPORTS RECORD REVENUES AND SECOND QUARTER 2026 RESULTS
LSL PHARMA GROUP: TARGETING SIGNIFICANT RAMP-UP IN COMMERCIAL PRODUCTION BEGINNING SEPTEMBER END, EXPECT STERI-MED TO DELIVER REVENUE GROWTH DURING H2
LSL PHARMA GROUP: EXPECT REMEDIATION PLAN TO BE SUBSTANTIALLY COMPLETED BY END OF 2026
Source text: ID:nCNW7brVQa
Further company coverage: LSL.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LSL Pharma
See all newsBrief: LSL Pharma Group Announces CFO Transition
Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches
Brief: Lsl Pharma Group Reports Record Revenues And Second Quarter 2026 Results
Brief: LSL Pharma Group Successfully Obtained U.S. FDA Certification For The Manufacturing Of Ophthalmic Ointments For Commercialization In The United States
Brief: LSL Pharma Group Announces Closing Of The Acquisition Of Juno Otc And Final $2M Closing Of Upsized $12M Offering